This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Zosano Pharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Nov 02

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Jun 29

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

May 26

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Apr 30

Zosano shares rise on migraine treatment NDA resubmission update

Apr 26

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Mar 15

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

Feb 01

Zosano Pharma requests FDA meeting for its Qtrypta application

Jan 04

Zosano Pharma EPS misses by $0.01

Nov 13

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Zosano Pharma onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:ZSAN.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2022	1	-55	-31	-29	N/A
12/31/2021	1	-30	-33	-28	N/A
9/30/2021	1	-31	-34	-28	N/A
6/30/2021	1	-31	-39	-31	N/A
3/31/2021	0	-33	-41	-31	N/A
12/31/2020	0	-33	-40	-32	N/A
9/30/2020	N/A	-34	-41	-33	N/A
6/30/2020	N/A	-35	-43	-33	N/A
3/31/2020	N/A	-37	-45	-36	N/A
12/31/2019	N/A	-38	-47	-35	N/A
9/30/2019	N/A	-39	-46	-34	N/A
6/30/2019	N/A	-37	-43	-33	N/A
3/31/2019	N/A	-37	-40	-30	N/A
12/31/2018	N/A	-35	-35	-29	N/A
9/30/2018	N/A	-33	-33	-28	N/A
6/30/2018	N/A	-32	-30	-27	N/A
3/31/2018	N/A	-30	-28	-26	N/A
12/31/2017	N/A	-29	-28	-27	N/A
9/30/2017	N/A	-29	-29	-28	N/A
6/30/2017	N/A	-29	-27	-26	N/A
3/31/2017	N/A	-29	-24	-24	N/A
12/31/2016	N/A	-30	-26	-26	N/A
9/30/2016	N/A	-30	-26	-25	N/A
6/30/2016	N/A	-31	-28	-27	N/A
3/31/2016	0	-32	-28	-27	N/A
12/31/2015	0	-28	N/A	-24	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if ZSAN.Q's forecast earnings growth is above the savings rate (2%).

Winst versus markt: Insufficient data to determine if ZSAN.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if ZSAN.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if ZSAN.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if ZSAN.Q's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if ZSAN.Q's Return on Equity is forecast to be high in 3 years time

This company is no longer active

Zosano Pharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus forecasts updated

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Consensus forecasts updated

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Consensus forecasts updated

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Consensus forecasts updated

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Zosano shares rise on migraine treatment NDA resubmission update

Consensus revenue estimates increase to US$5.17m

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Earnings miss expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: US$1.93

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

New 90-day high: US$0.81

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Zosano Pharma requests FDA meeting for its Qtrypta application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

Zosano Pharma EPS misses by $0.01

New 90-day low: US$0.36

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

Price target lowered to US$2.00

New 90-day low: US$0.64

New 90-day low: US$0.70

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - US$1.69

New 90-day high - US$1.22

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven